Genesis Therapeutics Inc. has divulged phosphatidylinositol 3-kinase alpha (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
Matchpoint Therapeutics Inc. has synthesized new diazepino-thieno-quinoxaline compounds acting as MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
Nimbus Saturn Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety covalently linked to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety linked via a linker.
Septerna Inc. has divulged compounds acting as mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of asthma, cancer, multiple sclerosis, obesity, osteoarthritis, psoriasis, rheumatoid arthritis and ulcerative colitis, among others.
Scientists at Institució Catalana de Recerca i Estudis Avançats and Universitat de Barcelona have identified three-prime repair exonuclease 2 (TREX2) inhibitors reported to be useful for the treatment of psoriasis, atopic dermatitis and ichthyosis.
Shandong Luye Pharmaceutical Co. Ltd. has described gonadotropin-releasing hormone receptor (GNRHR) antagonists reported to be useful for the treatment of acne, cancer, dysmenorrhea, endometriosis, uterine fibroids (myoma), infertility, precocious puberty and premenstrual syndrome, among others.
Scenic Immunology BV has disclosed glutaminyl-peptide cyclotransferase (QPCT; QC) and/or glutaminyl-peptide cyclotransferase-like protein (QPCTL; isoQC) inhibitors reported to be useful for the treatment of cancer.
Hebei Wutu Pharmaceutical Co. Ltd. has synthesized transient receptor potential cation channel subfamily V member 4 (TRPV4) antagonists reported to be useful for the treatment of liver cancer, cirrhosis, hepatic fibrosis, chronic hepatitis B and liver failure.
RSS